183 related articles for article (PubMed ID: 34723709)
1. Low disease activity state in juvenile-onset systemic lupus erythematosus.
Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
[TBL] [Abstract][Full Text] [Related]
3. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
[TBL] [Abstract][Full Text] [Related]
4. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
[TBL] [Abstract][Full Text] [Related]
5. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
[TBL] [Abstract][Full Text] [Related]
6. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
[TBL] [Abstract][Full Text] [Related]
7. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
[TBL] [Abstract][Full Text] [Related]
8. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
[TBL] [Abstract][Full Text] [Related]
10. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
11. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
Pawlak-Buś K; Schmidt W; Leszczyński P
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
[TBL] [Abstract][Full Text] [Related]
12. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432
[TBL] [Abstract][Full Text] [Related]
13. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.
Hao Y; Oon S; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Morand EF; Nikpour M; Zhang Z
Clin Rheumatol; 2022 Feb; 41(2):357-366. PubMed ID: 34595670
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE.
Cody EM; Wilson BE; Ogbu EA; Huggins JL; Chen C; Qiu T; Ting TV; Flores F; Huang B; Brunner HI
Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37253553
[TBL] [Abstract][Full Text] [Related]
15. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
[TBL] [Abstract][Full Text] [Related]
16. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
17. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
Babaoglu H; Li J; Goldman D; Magder LS; Petri M
Lupus; 2019 Dec; 28(14):1648-1655. PubMed ID: 31694446
[TBL] [Abstract][Full Text] [Related]
18. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Lee AL; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Morand EF; Nikpour M;
Arthritis Res Ther; 2016 Nov; 18(1):260. PubMed ID: 27829463
[TBL] [Abstract][Full Text] [Related]
19. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
[TBL] [Abstract][Full Text] [Related]
20. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand EF; Abreu G; Furie RA; Golder V; Tummala R
Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
